Belsomra Food & Supplement Interactions: What You Need to Know Before Taking Suvorexant

How Suvorexant Works: The Orexin System Explained

Suvorexant blocks both OX1R and OX2R orexin receptors in the hypothalamus, cutting off the wake-promoting signal that orexin-A and orexin-B normally supply. This mechanism differs fundamentally from benzodiazepines and Z-drugs, which activate GABA-A receptors non-selectively across the brain. Because suvorexant targets the switch that keeps you awake rather than broadly depressing CNS activity, its side-effect and interaction profile differs from older sedative-hypnotics in several clinically meaningful ways.

The Orexin Pathway and Why It Matters for Interactions

Orexin neurons in the lateral hypothalamus project to the locus coeruleus, dorsal raphe, and tuberomammillary nucleus, all regions that drive arousal. Blocking OX1R and OX2R simultaneously suppresses this wake drive without occupying GABA sites. That selectivity means suvorexant does not directly potentiate GABA-A the way alcohol does, yet CNS depression is still additive when both are combined, because downstream sedation pathways converge.

The key Phase 3 program by Herring et al. (Lancet Neurol 2014, N=1,021) demonstrated that suvorexant 15/20 mg and 30/40 mg reduced wake after sleep onset (WASO) and latency to persistent sleep (LPS) versus placebo at months 1 and 3 (P<0.001 for both doses on WASO at month 1). The study used polysomnography as an objective endpoint, lending it regulatory weight the self-report-only trials of older agents lack.

CYP3A4: The Metabolic Choke Point

FDA pharmacology review data confirm that CYP3A4 accounts for the vast majority of suvorexant oxidative metabolism. CYP2C19 contributes a minor share. This narrow metabolic route means any food, drink, or supplement that inhibits CYP3A4 raises suvorexant exposure, while inducers lower it. Understanding which everyday foods and over-the-counter supplements hit CYP3A4 is the core of safe suvorexant prescribing.

Grapefruit and Grapefruit Juice: The Most Documented Food Interaction

Grapefruit and grapefruit juice contain furanocoumarins, primarily bergapten and 6',7'-dihydroxybergamottin, that irreversibly inactivate intestinal CYP3A4. A single 8-oz glass can suppress intestinal CYP3A4 activity for up to 24 hours. For drugs with moderate-to-high first-pass CYP3A4 metabolism, this translates into meaningfully elevated AUC values.

Magnitude of the Interaction

The FDA label for suvorexant classifies grapefruit as a moderate CYP3A4 inhibitor interaction concern, consistent with the agency's drug interaction guidance. For reference, ketoconazole (a strong CYP3A4 inhibitor) increased suvorexant AUC approximately 3-fold in interaction studies; moderate inhibitors such as grapefruit constituents typically increase AUC 1.5- to 2-fold for CYP3A4-sensitive substrates. That range is sufficient to push a patient taking the already-maximal approved dose of 20 mg into a plasma exposure equivalent to a pharmacologically supra-therapeutic dose.

Clinical Consequences

Elevated suvorexant exposure extends the time the drug remains above its pharmacodynamic threshold. Next-morning grogginess, impaired driving performance, and delayed psychomotor recovery are the practical risks. A 2019 analysis in Clinical Pharmacology & Therapeutics found that sedative-hypnotic plasma levels on waking correlate directly with simulated driving impairment scores. Patients should avoid all grapefruit products on days they take suvorexant. Seville oranges and tangelos carry similar furanocoumarin loads and should also be avoided.

What About Other Citrus Fruits?

Standard navel oranges, clementines, lemons, and limes do not contain furanocoumarins at clinically relevant concentrations. Bailey et al. (Br J Clin Pharmacol, 2013) catalogued furanocoumarin content across citrus varieties and confirmed that common sweet oranges pose no CYP3A4 inhibition risk.

Alcohol: Additive CNS Depression

Alcohol does not inhibit CYP3A4 at typical social-drinking concentrations. The interaction with suvorexant is pharmacodynamic, not pharmacokinetic. Both substances suppress CNS arousal through independent but convergent pathways, suvorexant via orexin blockade, ethanol via GABA-A potentiation and NMDA antagonism. The net effect is additive sedation that exceeds what either agent produces alone.

What the Evidence Shows

The FDA pharmacology review included a dedicated alcohol interaction study showing increased subjective sedation scores and impaired psychomotor performance when suvorexant 20 mg was co-administered with 0.6 g/kg ethanol versus either agent alone. A 2016 review in Sleep Medicine Reviews confirmed that alcohol plus sedative-hypnotics produces significantly greater next-morning impairment than either alone across multiple drug classes.

The "Nightcap" Problem

Some patients with insomnia use alcohol as a sleep aid before adding a prescription hypnotic. This is common and dangerous. Alcohol fragments sleep architecture in the second half of the night while suvorexant is still active, the combination worsens total sleep quality even as it deepens early sedation. The American Academy of Sleep Medicine (AASM) clinical practice guideline (2017) states explicitly that alcohol use should be assessed and addressed before initiating pharmacotherapy for insomnia.

Meals and Timing: How Food Affects Suvorexant Absorption

Suvorexant absorption is not blocked by food, but it is delayed. A high-fat, high-calorie meal (approximately 800 to 1,000 kcal, 50% fat) delays median Tmax from roughly 2 hours to approximately 3.5 hours post-dose, according to FDA clinical pharmacology review data. The overall AUC is unchanged, but delayed peak plasma concentration means slower sleep onset.

Practical Dosing Guidance

The prescribing information advises taking suvorexant within 30 minutes of bedtime and not within or shortly after a meal for fastest onset. Patients who eat dinner 2 to 3 hours before bedtime and then take suvorexant on an empty stomach will reach peak plasma levels closer to the intended sleep window. A light snack (fewer than 300 kcal, low fat) has a clinically negligible effect on Tmax in pharmacokinetic modeling studies.

Melatonin: Low Pharmacokinetic Risk, Some Pharmacodynamic Overlap

Melatonin is the most commonly used OTC sleep supplement in the United States. Its receptor targets, MT1 and MT2 in the suprachiasmatic nucleus, differ from orexin receptors, and melatonin does not inhibit CYP3A4 at typical supplement doses (0.5 to 10 mg). No direct pharmacokinetic interaction with suvorexant has been published in peer-reviewed literature to date.

Where the Overlap Matters

Despite the distinct receptor profiles, Lemoine et al. (Sleep, 2007) demonstrated that melatonin at doses above 5 mg produces measurable sedation in older adults beyond its circadian phase-shifting effect. Combining 5 to 10 mg melatonin with suvorexant 20 mg may produce more morning grogginess than either agent alone, a pharmacodynamic overlap, not a pharmacokinetic one. Patients using melatonin alongside suvorexant should start at the lowest melatonin dose (0.5 mg) and assess next-day function before increasing.

Valerian Root: Weak Evidence, Real Sedative Concern

Valerian (Valeriana officinalis) is sold as a sleep aid at doses of 300 to 600 mg. Its proposed mechanism involves partial GABA-A modulation and possible adenosine effects, though a 2020 Cochrane review found no high-quality evidence for efficacy beyond placebo. Mechanistically, GABA-A modulation by valerian compounds creates the same pharmacodynamic overlap concern as alcohol: additive CNS depression on top of suvorexant's orexin-blocking sedation.

CYP Enzyme Considerations

Several valerenic acid derivatives have shown weak CYP3A4 inhibition in in-vitro assays. Hellum et al. (Phytomedicine, 2010) demonstrated that valerian extracts inhibit CYP3A4 activity in human liver microsomes at concentrations achievable with high commercial doses. Whether this translates to a clinically significant rise in suvorexant AUC in vivo remains unstudied, but prescribers should note the theoretical pharmacokinetic risk alongside the pharmacodynamic one. Patients should not combine valerian with suvorexant without physician review.

Kava (Piper methysticum): The Highest-Risk Supplement

Kava deserves a separate and strongly worded section. Kavalactones produce sedation through GABA-A modulation, voltage-gated sodium channel inhibition, and dopamine receptor effects, making the pharmacodynamic CNS depression risk with suvorexant substantial. Beyond sedation, kava is associated with serious hepatotoxicity.

Hepatotoxicity and the FDA Warning

The FDA issued a consumer advisory on kava and liver injury citing reports of liver failure, cirrhosis, and hepatitis, including cases requiring liver transplant. This risk is independent of suvorexant but becomes a double concern because patients with impaired hepatic function clear suvorexant more slowly: FDA pharmacology data show that severe hepatic impairment increases suvorexant AUC by approximately 50%. Kava-induced liver damage could therefore convert a normally cleared suvorexant dose into a supra-therapeutic exposure.

In-Vitro CYP3A4 Data

Mathews et al. (Drug Metab Dispos, 2005) showed that kavalactone concentrations achieved in human plasma after standard kava supplement doses are sufficient to inhibit CYP3A4 activity by 40 to 60% in vitro. Clinical pharmacokinetic studies in humans are lacking, but the combination of pharmacodynamic CNS depression, possible CYP3A4 inhibition, and hepatotoxicity risk makes kava one of the few supplements that warrants an absolute avoidance recommendation alongside suvorexant.

Cannabidiol (CBD): Emerging Interaction Signal

CBD is now widely available as a dietary supplement and is often self-administered for sleep or anxiety. CBD is a potent inhibitor of CYP3A4 and CYP2C19 at doses above approximately 300 mg/day, both enzymes involved in suvorexant metabolism.

Pharmacokinetic Evidence

Birdwell et al. (Clin Pharmacol Ther, 2020) reviewed CBD's drug interaction potential and concluded that CBD at therapeutic doses (used in Epidiolex trials at 5 to 20 mg/kg/day for epilepsy) significantly inhibits CYP3A4 and CYP2C19. Lower OTC supplement doses (25 to 100 mg) produce less inhibition, but the pharmacokinetic risk is dose-dependent and not absent. A patient taking 100 mg CBD nightly plus suvorexant 20 mg may experience meaningfully elevated suvorexant plasma levels compared with suvorexant alone.

Pharmacodynamic Overlap

Beyond enzyme inhibition, CBD itself produces dose-dependent sedation. Babson et al. (Curr Psychiatry Rep, 2017) reviewed CBD and sleep and found that higher CBD doses (160 mg) increased total sleep time in human subjects. The combination of a sedating CYP3A4 inhibitor with a CYP3A4-metabolized sedative-hypnotic represents layered risk that clinicians should discuss explicitly with patients.

St. John's Wort: CYP3A4 Induction Reduces Efficacy

St. John's Wort (Hypericum perforatum) is used for mild depression and anxiety and is widely available without prescription. It is a potent inducer of CYP3A4 and P-glycoprotein.

Reduced Suvorexant Efficacy

CYP3A4 induction accelerates suvorexant metabolism, lowering plasma AUC and shortening the drug's effective duration. Markowitz et al. (Clin Pharmacol Ther, 2003) demonstrated that St. John's Wort reduced the AUC of midazolam (another CYP3A4 substrate) by approximately 50% after 14 days of co-administration. A proportional reduction in suvorexant AUC would render a 10 mg or 15 mg dose pharmacologically subtherapeutic. The FDA drug interaction guidance classifies St. John's Wort as a strong CYP3A4 inducer; suvorexant's label contraindicates concurrent use with strong inducers.

Magnesium Glycinate and L-Theanine: Lower-Risk Options

Not all sleep supplements carry significant interaction risk with suvorexant. Magnesium glycinate at doses of 200 to 400 mg and L-theanine at 100 to 200 mg are two commonly used options with distinct mechanisms.

Magnesium

Magnesium modulates NMDA receptors and may reduce cortisol-driven hyperarousal. Abbasi et al. (J Res Med Sci, 2012) showed magnesium supplementation improved sleep efficiency in 46 elderly adults versus placebo. Magnesium does not inhibit CYP3A4 and does not produce clinically significant sedation at standard doses. Pharmacokinetic and pharmacodynamic interaction risk with suvorexant is low. High doses above 500 mg/day can cause gastrointestinal side effects and, in patients with renal impairment, hypermagnesemia, concerns separate from suvorexant.

L-Theanine

L-theanine, an amino acid from green tea, promotes alpha-wave EEG activity without causing overt sedation. Hidese et al. (Nutrients, 2019) found 200 mg L-theanine improved self-reported sleep quality in 30 adults over 4 weeks versus placebo, with no significant sedation signal. L-theanine does not inhibit CYP enzymes at standard doses and is not expected to alter suvorexant pharmacokinetics. It represents a lower-risk adjunct for patients who feel suvorexant alone is insufficient, though co-use should still be disclosed to the prescriber.

Interaction Summary Table

| Substance | Interaction Type | Mechanism | Clinical Action | |---|---|---|---| | Grapefruit / juice | Pharmacokinetic | CYP3A4 inhibition, raised AUC | Avoid completely | | Alcohol | Pharmacodynamic | Additive CNS depression | Avoid completely | | Kava | Both | GABA-A + CYP3A4 inhibition + hepatotoxicity | Avoid completely | | CBD (high dose) | Both | CYP3A4 inhibition + sedation | Avoid or reduce; disclose to prescriber | | St. John's Wort | Pharmacokinetic | CYP3A4 induction, reduced AUC | Contraindicated per label | | Valerian | Both | Weak CYP3A4 inhibition + GABA-A sedation | Discontinue before starting suvorexant | | Melatonin | Pharmacodynamic | Additive sedation at doses above 5 mg | Use lowest effective dose (0.5 mg); monitor | | Magnesium glycinate | Minimal | No CYP involvement | Generally safe; standard doses | | L-theanine | Minimal | No CYP involvement | Generally safe; disclose use | | Seville oranges / tangelos | Pharmacokinetic | Furanocoumarin CYP3A4 inhibition | Avoid (same class as grapefruit) |

Special Populations: When Food and Supplement Interactions Carry Extra Risk

Older Adults

Adults over 65 have reduced CYP3A4 activity at baseline, meaning any additional inhibition from grapefruit or CBD compounds an already-elevated exposure risk. The AASM insomnia guideline (2017) recommends suvorexant be used at the lowest effective dose in older adults. A 10 mg starting dose combined with avoidance of all CYP3A4 inhibitors is advisable in this group.

Hepatic Impairment

Suvorexant is not recommended in patients with severe hepatic impairment, per the FDA prescribing information. Moderate impairment increases AUC approximately 17%, which is clinically acceptable at lower doses. Kava's hepatotoxicity risk makes it particularly dangerous in this setting.

Patients on CYP3A4-Inhibiting Medications

Some patients may already be taking moderate CYP3A4 inhibitors such as fluconazole, diltiazem, or erythromycin for unrelated conditions. Adding grapefruit or kava on top of a drug-drug CYP3A4 inhibition represents compounding risk. The label caps suvorexant at 10 mg when used with moderate CYP3A4 inhibitors. The same principle applies when a food-based or supplement-based CYP3A4 inhibitor is also present.

How to Talk to Your Prescriber

Patients often do not volunteer supplement use because they assume natural products are harmless. A 2019 JAMA survey (N=26,365) found that 57.6% of U.S. Adults reported prescription drug use and that a substantial proportion used dietary supplements concurrently, yet fewer than half disclosed supplement use to their physicians. For suvorexant specifically, disclosure of grapefruit consumption, alcohol use, CBD products, and any herbal sleep supplement is necessary before dose selection.

Bring a full list of supplements, including brand names and doses, to every visit. The NIH Office of Dietary Supplements interaction fact sheet framework provides a searchable database that both patients and clinicians can use to check supplement-drug interaction status before adding or removing a product.